Literature DB >> 2531569

Teicoplanin metabolism in rats.

L F Zerilli1, L Cavenaghi, A Bernareggi, A Assandri.   

Abstract

This study was done to see whether teicoplanin undergoes metabolic transformation in rats. Sprague-Dawley rats were given 7.6 mg of [14C]teicoplanin (904 U/mg, 7.6 muCi/mg) per kg intravenously; 73.2 +/- 4.0% of the administered radioactivity and 59.1 +/- 4.8% of the administered microbiological activity were recovered in the 24-h urine samples. The difference between these two values was due to adsorption of teicoplanin to the urinary sediment, making some of the antibiotic not available for microbiological determination. In fact, after a sample or urine was filtered through an Acrodisc (0.45 micron pore size), radiochemical and microbiological data for the filtrate were very similar. Possible metabolites were looked for by high-performance liquid chromatographic analysis of the teicoplanin complex composition in the urine samples, with both UV and radioactivity detection. The quantitation, based on the 14C percentage in each peak, showed that no more than 3 to 5% of the [14C]teicoplanin underwent metabolic and/or chemical transformation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2531569      PMCID: PMC172756          DOI: 10.1128/AAC.33.10.1791

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Determination of teicoplanin in human plasma and urine by affinity and reversed-phase high-performance liquid chromatography.

Authors:  E Riva; N Ferry; A Cometti; G Cuisinaud; G G Gallo; J Sassard
Journal:  J Chromatogr       Date:  1987-10-09

Review 2.  Structure and mechanism of action of teicoplanin.

Authors:  F Parenti
Journal:  J Hosp Infect       Date:  1986-03       Impact factor: 3.926

3.  Structure and conformation of epimers derived from the antibiotic teicoplanin.

Authors:  J C Barna; D H Williams; P Strazzolini; A Malabarba; T W Leung
Journal:  J Antibiot (Tokyo)       Date:  1984-10       Impact factor: 2.649

4.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

5.  Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. IV. Separation and characterization of the components of teichomycin (teicoplanin).

Authors:  A Borghi; C Coronelli; L Faniuolo; G Allievi; R Pallanza; G G Gallo
Journal:  J Antibiot (Tokyo)       Date:  1984-06       Impact factor: 2.649

6.  Teicoplanin, antibiotics from Actinoplanes teichomyceticus nov. sp. VI. Chemical degradation: physico-chemical and biological properties of acid hydrolysis products.

Authors:  A Malabarba; P Strazzolini; A Depaoli; M Landi; M Berti; B Cavalleri
Journal:  J Antibiot (Tokyo)       Date:  1984-09       Impact factor: 2.649

7.  Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics.

Authors:  R Pallanza; M Berti; B P Goldstein; E Mapelli; E Randisi; R Scotti; V Arioli
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

8.  Isolation and structure determination of the main related substances of teicoplanin, a glycopeptide antibiotic.

Authors:  A Cometti; G G Gallo; J Kettenring; G B Panzone; G Tuan; L F Zerilli
Journal:  Farmaco Sci       Date:  1988-12

Review 9.  Pharmacokinetics of vancomycin.

Authors:  R C Moellering
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

10.  Pharmacokinetics of [14C]teicoplanin in male rats after single intravenous dose.

Authors:  A Bernareggi; L Cavenaghi; A Assandri
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

View more
  1 in total

1.  Teicoplanin metabolism in humans.

Authors:  A Bernareggi; A Borghi; M Borgonovi; L Cavenaghi; P Ferrari; K Vékey; M Zanol; L F Zerilli
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.